LUND (SWEDEN), Aug. 11,
2021 /PRNewswire/ -- Immunovia will publish the company's
interim report for the period January 1 -
June 30, 2021 on Thursday, August 19,
2021 at 16:00 CEST. Investors,
analysts and media are invited to a telephone conference with web
presentation on the same day at 16:30
CEO Patrik Dahlen will present
Immunovia and comment on the interim report.
Medical Director Dr. Thomas King,
Sr. Marketing Director US Cindy Callahan and CEO
Patrik Dahlen will also provide an
update about the marketing plans following the launch of the
IMMRayTM PanCan-d test. The presentations will be
held in English, followed by a Q&A session.
To participate in the telephone conference, please call:
Sweden: +46 8 505 583
+44 333 300 90 31
+1 631 913 14 22 PIN: 38748855#
Belgium: +32 240 358
Denmark: +45 787 232
France: +33 170 750
+49 692 222 391 66
Norway: +47 239 639
+41 225 805 976
+31 207 219 496
Link to the
Following the telephone conference, a recording will be
available on Immunovia's website (www.immunovia.com).
For more information, please contact:
Patrik Dahlen, CEO Immunovia
Tel: +46 73 376 76 64
Immunovia AB is a diagnostic company that is developing and
commercializing highly accurate blood tests for the early detection
of cancer and autoimmune diseases based on Immunovia's
proprietary test platform called IMMray™. Tests are based on
antibody biomarker microarray analysis using advanced
machine-learning and bioinformatics to single-out a set of relevant
biomarkers that indicate a certain disease. Thus, forming a unique
"disease biomarker signature".
The company was founded in 2007, based on cancer studies and
ground-breaking research in the Department of Immuntechnology at
Lund University and CREATE Health
Cancer Center, Sweden.
The first product, IMMray™ PanCan-d, is undergoing clinical
evaluation in some of the world's largest clinical studies for
high risk groups in pancreatic cancer, PanFAM-1, PanSYM-1 and
In 2017, Immunovia, Inc. was established in Marlborough, Massachusetts, USA. The IMMray™
PanCan-d test, the first blood-based test dedicated to the early
detection of pancreatic cancer on the market, is offered as a
laboratory developed test (LDT) exclusively through Immunovia, Inc.
For more information see: www.immunoviainc.com. The European launch
plan will be communicated during the second half of 2021.
Immunovia's shares (IMMNOV) are listed on Nasdaq Stockholm. For
more information, please visit www.immunovia.com.
This information was brought to you by Cision
The following files are available for download: